Takeda Pharmaceutical (TAK) Earnings Date, Estimates & Call Transcripts $14.46 +0.10 (+0.70%) Closing price 03:59 PM EasternExtended Trading$14.45 -0.01 (-0.07%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Takeda Pharmaceutical Earnings Summary Takeda Pharmaceutical issued Q1 2026 earnings on July 30, 2025, reporting an EPS of $0.52, which beat analysts' consensus estimates of $0.47 by $0.05. Quarterly revenue was reported to be $7.45 billion, below the consensus estimate of $7.96 billion. With a trailing EPS of $0.30 and a P/E Ratio of 9.32, Takeda Pharmaceutical's earnings are expected to grow 0.61% next year, from $1.64 to $1.65 per share. Latest Q1 Earnings DateJul. 30EstimatedConsensus EPS (Jul. 30) $0.47 Actual EPS (Jul. 30) $0.52 Beat By $0.05 Actual Revenue (Jul. 30) $7.45BQ1 2026 Earnings ResourcesQ1 2026 Earnings ReportConference Call Transcript & Audio Interim Report Slide DeckSlide DeckFull Screen Slide DeckPowered by Get Takeda Pharmaceutical Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Takeda Pharmaceutical and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataTAK Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TAK Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Takeda Pharmaceutical Analyst EPS EstimatesCurrent Year EPS Consensus Estimate $1.64 EPSNext Year EPS Consensus Estimate $1.65 EPS Takeda Pharmaceutical Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails7/30/2025Q1 2026$0.47$0.52+$0.05$0.27$7.96B$7.45B5/8/2025Q4 2025$0.24$0.16 -$0.08-$0.21$8.02B$7.34B1/30/2025Q3 2025$0.34$0.42+$0.08$0.05--7/31/2024Q1 2025$0.37$0.56+$0.19$0.93-$7.75B2/1/2024Q3 2024-$0.51-$0.79-$7.52B10/26/2023Q2 2024-$0.50-$0.86-$6.94B Takeda Pharmaceutical Earnings - Frequently Asked Questions When did Takeda Pharmaceutical announce their last quarterly earnings? Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earning data on Wednesday, July 30, 2025. Learn more on TAK's earnings history. What guidance has Takeda Pharmaceutical issued on next quarter's earnings? Takeda Pharmaceutical issued an update on its FY 2025 earnings guidance on Wednesday, July, 30th. The company provided earnings per share (EPS) guidance of 3.360-3.360 for the period. The company issued revenue guidance of $31.3 billion-$31.3 billion. Did Takeda Pharmaceutical beat their earnings estimates last quarter? In the previous quarter, Takeda Pharmaceutical (NYSE:TAK) reported $0.52 earnings per share (EPS) to beat the analysts' consensus estimate of $0.47 by $0.05. Learn more on analysts' earnings estimate vs. TAK's actual earnings. How can I listen to Takeda Pharmaceutical's earnings conference call? The conference call for Takeda Pharmaceutical's latest earnings report can be listened to online. Listen to Conference Call How can I read Takeda Pharmaceutical's conference call transcript? The conference call transcript for Takeda Pharmaceutical's latest earnings report can be read online. Read Transcript How much revenue does Takeda Pharmaceutical generate each year? Takeda Pharmaceutical (NYSE:TAK) has a recorded annual revenue of $30.09 billion. How much profit does Takeda Pharmaceutical generate each year? Takeda Pharmaceutical (NYSE:TAK) has a recorded net income of $712.33 million. TAK has generated $0.30 earnings per share over the last four quarters. What is Takeda Pharmaceutical's price-to-earnings ratio? Takeda Pharmaceutical (NYSE:TAK) has a trailing price-to-earnings ratio of 9.32 and a forward price-to-earnings ratio of 8.82. What is Takeda Pharmaceutical's EPS forecast for next year? Takeda Pharmaceutical's earnings are expected to grow from $1.64 per share to $1.65 per share in the next year, which is a 0.61% increase. More Earnings Resources from MarketBeat Related Companies Sanofi Earnings Results GSK Earnings Results argenex Earnings Results BeOne Medicines Earnings Results BioNTech Earnings Results Summit Therapeutics Earnings Results Insmed Earnings Results Teva Pharmaceutical Industries Earnings Results Genmab A/S Earnings Results Dr. Reddy's Laboratories Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Airbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a Rally This page (NYSE:TAK) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
